By Sherri Oslick --
About Court Report: Each week we will report briefly on recently filed biotech and pharma cases.
Ferring B.V. v. Watson Pharmaceuticals, Inc. et al.
3:11-cv-00481; filed July 7, 2011 in the District Court of Nevada
• Plaintiff: Ferring B.V.
• Defendants: Watson Pharmaceuticals, Inc.; Watson Laboratories, Inc.; Watson Laboratories, Inc. – Florida; Watson Pharma, Inc.
Infringement of U.S. Patent No. 7,947,739 ("Tranexamic Acid Formulations," issued May 24, 2011) following a Paragraph IV certification as part of Watson's filing of an ANDA to manufacture a generic version of Ferring's Lysteda® (tranexamic acid, used to treat heavy menstrual bleeding). View the complaint here.
Intervet Inc. et al. v. Boehringer Ingelheim Vetmedica Inc.
1:11-cv-00595; filed July 6, 2911 in the District Court of Delaware
• Plaintiffs: Intervet Inc. d/b/a Merck Animal Health; Arizona Board of Regents
• Defendant: Boehringer Ingelheim Vetmedica Inc.
Infringement of U.S. Patent No. 5,610,059 ("Etiological Agent for Porcine Enteritis," issued March 11, 1997) based on Boehringer's manufacture and sale of its Enterisol® Ileitis product. View the complaint here.
Shire LLC et al. v. Roxane Laboratiores, Inc.
2:11-cv-03886; filed July 6, 2011 in the District Court of New Jersey
• Plaintiffs: Shire LLC; Shire Development Inc.
• Defendant: Roxane Laboratiores, Inc.
Shire LLC et al. v. Sandoz Inc.
3:11-cv-03787; filed June 30, 2011 in the District Court of New Jersey
• Plaintiffs: Shire LLC; Shire Development Inc.
• Defendant: Sandoz Inc.
Shire LLC et al. v. Amneal Pharmaceuticals, LLC
3:11-cv-03781; filed June 30, 2011 in the District Court of New Jersey
• Plaintiffs: Shire LLC; Shire Development Inc.
• Defendant: Amneal Pharmaceuticals, LLC
The complaints in these cases are substantially identical. Infringement of U.S. Patent Nos. 7,105,486 ("Abuse-resistant amphetamine compounds," issued September 12, 2006), 7,223,735 ("Abuse resistant lysine amphetamine compounds," issued May 29, 2007), 7,655,630 ("Abuse-resistant amphetamine prodrugs," issued February 2, 2010), 7,659,253 ("Abuse-resistant amphetamine prodrugs," issued February 9, 2010), 7,659,254 ("Abuse-resistant amphetamine prodrugs," issued February 9, 2010), 7,662,787 ("Abuse resistant lysine amphetamine compounds," issued February 16, 2010), 7,671,030 ("Abuse-resistant amphetamine prodrugs," issued March 2, 2010), 7,671,031 ("Abuse-resistant amphetamine prodrugs," issued March 2, 2010), 7,674,774 ("Abuse-resistant amphetamine prodrugs," issued March 9, 2010), 7,678,770 ("Abuse-resistant amphetamine prodrugs," issued March 16, 2010), 7,678,771 ("Abuse-resistant amphetamine prodrugs," issued March 16, 2010), 7,687,466 ("Abuse-resistant amphetamine prodrugs," issued March 30, 2010), 7,687,467 ("Abuse-resistant amphetamine prodrugs," issued March 30, 2010), 7,700,561 ("Abuse-resistant amphetamine prodrugs," issued April 20, 2010), 7,718,619 ("Abuse-resistant amphetamine prodrugs," issued May 18, 2010), 7,723,305 ("Abuse-resistant amphetamine prodrugs," issued May 25, 2010) following a Paragraph IV certification as part of Sandoz's filing of an ANDA to manufacture a generic version of Shire's Vyvanse® (lisdexamfetamine dimesylate, used to treat Attention Deficit Hyperactivty Disorder). View the Sandoz complaint here. [NB: The complaint against Amneal does not assert U.S. Patent No. 7,659,254.]
Alcon Pharmaceuticals Ltd. et al. v. Lupin Ltd. et al.
1:11-cv-00587; filed July 1, 2011 in the District Court of Delaware
• Plaintiffs: Alcon Pharmaceuticals Ltd.; Alcon Research Ltd.
• Defendants: Lupin Ltd.; Lupin Pharmaceuticals Inc.
Infringement of U.S. Patent Nos. 6,716,830 ("Ophthalmic Antibiotic Compositions Containing Moxifloxacin," issued April 6, 2004) and 7,671,070 ("Method of Treating Ophthalmic Infections with Moxifloxacin Compositions," issued March 2, 2010) following a Paragraph IV certification as part of Lupin's filing of an ANDA to manufacture a generic version of Alcon's Vigamox® (moxifloxacin, used to treat bacterial conjunctivitis). View the complaint here.
Orexo AB v. Mylan Pharmaceuticals Inc. et al.
3:11-cv-03788; filed June 30, 2011 in the District Court of New Jersey
• Plaintiff: Orexo AB
• Defendants: Mylan Pharmaceuticals Inc.; Mylan, Inc.
Infringement of U.S. Patent No. 6,761,910 ("Pharmaceutical Composition for the Treatment of Acute Disorders," issued July 13, 2004), licensed to Meda Pharmaceuticals, following a Paragraph IV certification as part of Mylan's filing of an ANDA to manufacture a generic version of Meda's Edluar (zolpidem sublingual tablets, used to treat short-term insomnia). View the complaint here.
Comments